| dc.description.abstract | Head and neck cancers (HNC) are extremely complex disease types and it is likely that chromosomalinstability is involved in the genetic mechanisms of its genesis. However, there is little information regardingthe background levels of chromosome instability in these patients. In this pilot study, we examined spontaneouschromosome instability in short-term lymphocyte cultures (72 hours) from 72 study subjects - 36 newlydiagnosed HNC squamous cell carcinoma patients and 36 healthy ethnic controls. We estimated chromosomeinstability (CIN) using chromosomal aberration (CA) analysis and nuclear level anomalies using the CytokinesisBlock Micronucleus Cytome Assay (CBMN Cyt Assay). The proliferation rates in cultures of peripheral bloodlymphocytes (PBL) were assessed by calculating the Cytokinesis Block Proliferation Index (CBPI). Our resultsshowed a significantly higher mean level of spontaneous chromosome type aberrations (CSAs), chromatidtype aberration (CTAs) dicentric chromosomes (DIC) and chromosome aneuploidy (CANEUP) in patients(CSAs, 0.0294±0.0038; CTAs, 0.0925±0.0060; DICs, 0.0213±0.0028; and CANEUPs, 0.0308±0.0035) comparedto controls (CSAs, 0.0005±0.0003; CTAs, 0.0058±0.0015; DICs, 0.0005±0.0003; and CANEUPs, 0.0052±0.0013)where p<0.001. Similarly, spontaneous nuclear anomalies showed significantly higher mean level of micronuclei(MNi), nucleoplasmic bridges (NPBs) and nuclear buds (NBUDs) among cases (MNi, 0.01867±0.00108;NPBs, 0.01561±0.00234; NBUDs, 0.00658±0.00068) compared with controls (MNi, 0.00027±0.00009; NPBs,0.00002±0.00002; NBUDs, 0.00011±0.00007).The evaluation of CBPI supported genomic instability in theperipheral blood lymphocytes showing a significantly lower proliferation rate in HNC patients (1.525±0.005552)compared to healthy subjects (1.686±0.009520 ) (p<0.0001). In conclusion, our preliminary results showed thatvisible spontaneous genomic instability and low rate proliferation in the cultured peripheral lymphocytes ofsolid tumors could be biomarkers to predict malignancy in early stages | en_US |
